

VDP Current Eligible Cohorts and Operational status

Version 1.8

30th November 2021

Correct at time of publication, weekly review



Summary of current position for primary courses and booster COVID-19 vaccination: **ADULTS**

Current at **30/11/2021**, valid until **08/12/2021** Check [Green Book](#) for full clinical details



ADULTS	Dose	Mechanism of Administration	Recommended Vaccine	National Booking System Status ³	Site Type	Walk in / Grab A Jab Status ³
Adults Cohorts 1-10	Primary Course: 2 doses ⁴ , minimum 8 weeks apart ²	Current PGDs and National Protocols ¹	Comirnaty® (Pfizer BioNTech), Spikevax® (Moderna) 0.5ml or Vaxzevria® (AstraZeneca)	1 st dose 2 nd dose Booster dose	HH [^] / HH ⁺ / PCN* / VC / CP <small>^HH do not cover all cohorts - only vaccinating HCWs and patients opportunistically</small> <small>*PCN – not all PCNs have opted in for Cohort 10 boosters</small>	1 st dose 2 nd dose Booster dose
	Booster: Eligible from 182 days post 2 nd dose ⁴	Current PGDs and National Protocols ¹	Comirnaty® (Pfizer BioNTech) or Spikevax® (Moderna) 0.25ml			
	Limited circumstances: dose interval from 5 months permitted with documentation of rationale About to commence immunosuppressive therapy: May be eligible from 4 months (~120 days) post 2 nd dose (GP/specialist decision)	Current PGD / National Protocol for Comirnaty® (Pfizer BioNTech) A local Patient Specific Direction for Spikevax® (Moderna) 0.25ml [or Vaxzevria® (AstraZeneca)]	[In limited circumstances Vaxzevria® (AstraZeneca)]			
Adults Cohorts 11-12	Primary Course: 2 doses ⁴ , minimum 8 weeks apart	Current PGDs and National Protocols ¹	Comirnaty® (Pfizer BioNTech) or Spikevax® (Moderna) 0.5ml	1 st dose 2 nd dose	HH ⁺ / PCN / VC / CP	1 st dose 2 nd dose
Adults Severely Immuno-compromised at time of 1st or 2nd dose	Primary course as per Cohorts 1-12 (2 doses ⁴ , minimum 8 weeks apart ²) PLUS Third primary dose Ideally 8 weeks after 2 nd dose ⁴ If in Cohorts 4 and 6, it is possible to receive a booster dose if at least 182 days after 2 nd dose, which can later be converted to the 3 rd dose	Current PGDs and National Protocols ¹ following GP/specialist review	Comirnaty® (Pfizer BioNTech) or Spikevax® (Moderna) 0.5ml [In some cases Vaxzevria® (AstraZeneca)]	3 rd dose booking not available	HH / HH ⁺ / PCN / VC / CP with letter from specialist/GP	Citizens can attend a walk in site with a GP/specialist letter for the 3 rd dose

Notable recent programme changes applicable to Adults:
 Revised PGDs and National Protocols for Comirnaty / Pfizer BioNTech published
 Cohort 10 eligible for Booster dose
 Green Book Chapter 14a revised

- ¹ A local Patient Specific Direction (PSD) can also be used
- ² Exception for those about to commence immunosuppressive therapy
- ³ Local booking systems may differ
- ⁴ Doses deferred until 4 weeks after onset of COVID-19 symptoms/positive PCR sample
- ⁵ Doses deferred until 12 weeks after onset of COVID-19 symptoms/positive PCR sample
- ⁶ Certain sites only – approved and/or self declaration*

Summary of current position for primary courses and booster COVID-19 vaccination: 16 – 17 years

Correct at **30/11/2021**, valid until **08/12/2021 (2 of 3)** Check [Green Book](#) for full clinical details



16 - 17 years	Dose	Mechanism of Administration	Recommended Vaccine	National Booking System Status ³	Site Type	Walk in / Grab A Job Status ³
16 – 17 years and in a risk group (Cohorts 1, 2, 4 or 6) Cohort 1 and 2 = work in health or social care Cohort 4 or 6 = clinical risk groups and other risk groups (carers or household contact of immunosuppressed)	Primary Course: 2 doses ⁴ , minimum 8 weeks apart ²	Current PGDs and National Protocols ¹	Comirnaty® (Pfizer BioNTech)	1 st dose	HH [^] / HH+ / PCN / VC / CP [^] HH do not cover all cohorts - only vaccinating HCWs and patients opportunistically	1 dose
	Booster: Eligible from 182 days post 2 nd dose ⁴ Limited circumstances: dose interval from 5 months permitted with documentation of rationale About to commence immunosuppressive therapy: May be eligible from 4 months (~120 days) post 2 nd dose (GP/specialist decision)					2 nd dose Booster 2 nd dose or booster with evidence (e.g. national invite, GP/consultant letter, proof of frontline HSCW employment)
16 – 17 years NOT in Cohorts 1, 2, 4 or 6*	Primary Course: 2 doses ⁵ , minimum 12 weeks apart Existing appointments booked with an 8 week interval for 17.75 < 18 year olds can be honoured if the young person consents to this	Current PGDs and National Protocols ¹	Comirnaty® (Pfizer BioNTech)	1 st dose 2 nd dose	HH+ / PCN / VC / CP	1 st dose ⁶ 2 nd dose ⁶
16 – 17 years and severely immunocompromised at time of 1st or 2nd dose*	Primary course as per Cohorts 4 and 6 (2 doses ⁴ , minimum 8 weeks apart ²) PLUS Third primary dose Ideally 8 weeks after 2 nd dose ⁴ If in Cohorts 4 and 6, it is possible to receive a booster dose if at least 182 days after 2 nd dose, which can later be converted to the 3 rd dose	Current PGDs and National Protocols ¹ following GP/Specialist review	Comirnaty® (Pfizer BioNTech)	3 rd dose booking not available	HH / HH+ / PCN / VC / CP with letter from GP/Specialist	Can attend an age appropriate walk in site ⁶ with a GP/Specialist letter for 3 rd dose

*All CP, VC & HH sites vaccinating must complete the readiness checklist and declare via Qflow first. See [here](#). PCN-led sites are not required to complete the readiness checklist but are strongly encouraged to review it & ensure their sites remain compliant.

Notable recent programme changes applicable to 16-17 year olds:

Revised PGDs and National Protocols for Comirnaty / Pfizer BioNTech published

16-17 year olds not in a risk group now eligible for 2nd doses

12-17 year olds not in a risk group require 12 week deferral post COVID-19 infection

17.75 < 18 year olds not in a risk group ('rising 18s') now incorporated into the group for 16-17 year olds not in a risk group

Green Book Chapter 14a revised

¹ A local Patient Specific Direction (PSD) can also be used

² Exception for those about to commence immunosuppressive therapy

³ Local booking systems may differ

⁴ Doses deferred until 4 weeks after onset of COVID-19 symptoms/positive PCR sample

⁵ Doses deferred until 12 weeks after onset of COVID-19 symptoms/positive PCR sample

⁶ Certain sites only – approved and/or self declaration*

Summary of current position for primary courses and booster COVID-19 vaccination: 12 – 15 years

Correct at 30/11/2021, valid until 08/12/2021 (3 of 3) Check [Green Book](#) for full clinical details



12 – 15 years	Dose	Mechanism of Administration	Recommended Vaccine	National Booking System Status ³	Site Type	Walk in / Grab A Jab Status ³
12 – 15 years in a risk group Either clinical risk (including cohort extension)* OR household contacts of immunocompromised*	Primary Course: 2 doses ⁴ , minimum 8 weeks apart	Current PGDs and National Protocols ¹	Comirnaty® (Pfizer BioNTech)	1 st dose	HH [^] / HH+ [^] / PCN Approved VC / CP ^HH/HH+ only opportunistically vaccinating patients with a clinical risk	1 st dose ⁶ 2 nd dose ⁶ with evidence (e.g. national invite, letter from GP)
12 – 15 years and severely immunocompromised at time of 1st or 2nd dose*	Primary course as per risk groups (2 doses ⁴ , minimum 8 weeks apart) PLUS Third primary dose Ideally 8 weeks after 2 nd dose ⁴	Current PGDs and National Protocols ¹ following GP/specialist review	Comirnaty® (Pfizer BioNTech)	3 rd dose booking not available	HH / HH+ / PCN Approved VC / CP with letter from GP/Specialist	Can attend an age appropriate walk in site ⁶ with a GP/Specialist letter for 3 rd dose
12 – 15 years not in a risk group*	Primary Course: 1 st dose ⁵	Current PGDs and National Protocols ¹	Comirnaty® (Pfizer BioNTech)	1 st dose	Schools Approved VC / CP / HH+ / PCN	1 st dose ⁶

*All CP, VC & HH sites vaccinating must complete the readiness checklist and declare via Qflow first. See [here](#). PCN-led sites are not required to complete the readiness checklist but are strongly encouraged to review it & ensure their sites remain compliant.

Notable recent programme changes applicable to 12-15 year olds:
 Revised PGDs and National Protocols for Comirnaty / Pfizer BioNTech published
 12-17 year olds not in a risk group require 12 week deferral post COVID-19 infection
 Green Book Chapter 14a revised

¹ A local Patient Specific Direction (PSD) can also be used

² Exception for those about to commence immunosuppressive therapy

³ Local booking systems may differ

⁴ Doses deferred until 4 weeks after onset of COVID-19 symptoms/positive PCR sample

⁵ Doses deferred until 12 weeks after onset of COVID-19 symptoms/positive PCR sample

⁶ Certain sites only – approved and/or self declaration*